Black seed oil at 1000 mg daily reduced inflammatory markers (IL-6) and fasting blood glucose in women with PCOS over 12 weeks, but showed no effect on insulin resistance or hormonal imbalances. evidence from a small, well-designed trial.
Polycystic ovary syndrome affects 5-10% of women of reproductive age and combines irregular menstrual cycles, hormonal imbalance, and metabolic dysfunction. The condition frequently includes elevated inflammation and insulin resistance, both of which contribute to the reproductive and metabolic complications that make PCOS difficult to manage. This randomized, double-blind, placebo-controlled trial tested whether black seed oil could address some of these underlying features.
Sixty women with PCOS were divided equally between groups receiving either 1000 mg of black seed oil daily or placebo for 12 weeks. The researchers measured fasting blood glucose, insulin levels, insulin resistance (HOMA-IR and QUICKI indices), inflammatory markers (IL-6), and hormonal levels (luteinizing hormone and total testosterone). They also tracked menstrual cycle characteristics like interval length and duration.
The results were mixed. In the black seed oil group, fasting blood glucose dropped significantly compared to placebo (8.16 mg/dL lower on average), and serum IL-6, a key inflammatory cytokine, also decreased significantly. The intermenstrual interval (time between periods) shortened in the intervention group, suggesting a modest improvement in cycle regularity. However, the study found no significant differences between groups for fasting insulin levels, insulin resistance indices, luteinizing hormone, or testosterone. Menstrual duration and other clinical PCOS manifestations showed no meaningful change.
The authors note that while the 12-week duration was adequate to detect changes in glucose and inflammation, it may have been too short to see effects on hormonal outcomes or more deeply embedded metabolic dysfunction. The magnitude of glucose reduction (8.16 mg/dL) was statistically significant but modest in clinical terms. The IL-6 reduction suggests the supplement may modulate immune activity, which is relevant since chronic low-grade inflammation is central to PCOS pathophysiology.
If you have PCOS, this study alone does not establish black seed oil as a primary treatment. The benefits detected were narrow: some glucose improvement and inflammation reduction, but no improvement in insulin resistance or hormone levels that drive the condition. Insulin resistance is often a core driver of PCOS symptoms, so the lack of effect on HOMA-IR or QUICKI is meaningful.
Black seed oil might play a supporting role alongside other interventions. Established approaches like resistance training, high-fiber diet, protein at every meal, and weight management remain the foundation for PCOS management, with stronger evidence behind them. If you are considering black seed oil, it should not replace these evidence-backed strategies.
The dose used here (1000 mg daily) is moderate and generally well-tolerated, but this was a single 12-week study in a relatively small sample. Larger, longer trials are needed to determine whether benefits persist, whether they translate to meaningful clinical outcomes (like improved fertility or better symptom control), and which patients are most likely to respond.
| Parameter | Details |
|---|---|
| Study Type | Randomized, double-blind, placebo-controlled trial |
| Sample Size | 60 women (30 per group) |
| Intervention | Black seed oil 1000 mg daily |
| Duration | 12 weeks |
| Primary Outcomes | Serum IL-6, fasting insulin, fasting blood glucose, insulin resistance indices |
| Secondary Outcomes | Menstrual cycle parameters, luteinizing hormone, total testosterone |
| Key Finding | Significant reduction in IL-6 and fasting glucose; no effect on insulin resistance or hormonal markers |
| Evidence Tier | B tier (well-designed RCT, modest sample size, short duration) |
| Journal | The Journal of Obstetrics and Gynaecology Research |
1. Study: Nigella sativa (Black Seed) Oil Alleviates the Serum Levels of IL-6 and Insulin in Patients With Polycystic Ovary Syndrome. PubMed. https://pubmed.ncbi.nlm.nih.gov/42601227/
2. Relevant background on PCOS epidemiology and pathophysiology: Consensus evidence on metabolic features in polycystic ovary syndrome has been reviewed in major clinical guidelines including the Rotterdam criteria and the Androgen Excess Society consensus.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.